Under the Nose Face Mask to Prevent Facial Pressure Ulcers During NIV for Acute Hypercapnic Respiratory Failure (AHRF) (UNDER PRESSURE)
Primary Purpose
Acute Hypercapnic Respiratory Failure
Status
Completed
Phase
Not Applicable
Locations
France
Study Type
Interventional
Intervention
Under-the-nose facemask
Over-the-nose facemask
Sponsored by
About this trial
This is an interventional other trial for Acute Hypercapnic Respiratory Failure focused on measuring facial pressure ulcers, noninvasive ventilation, acute hypercapnic respiratory failure
Eligibility Criteria
Inclusion Criteria:
- Acute hypercapnic respiratory failure
- Initiation of NIV
- Estimated cumulative time of NIV upper than 12 hours for the first 48 hours of hospitalization
Exclusion Criteria:
- Contraindication for NIV (respiratory arrest, impossibility to fit the mask)
- Intubated patient
- Patient with a tracheostomy
- Post-extubation respiratory failure
- Patient exhibiting facial ulcers or skin lesions located at the insertion points of the mask before its hospitalization
- Person declining NIV
- Pregnancy
- Dying person
Sites / Locations
- Centre Hospitalier Arras
- Centre Hospitalier Lens
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Experimental
Arm Label
Over-the-nose facemask
Under-the-nose facemask
Arm Description
The AF541 oro-nasal mask is used with the over-the-nose mask cushion.
The AF541 oro-nasal mask is used with the under-the-nose mask cushion.
Outcomes
Primary Outcome Measures
Change of the incidence of facial pressure ulcers in the experimental arm compared to the control arm, within the first 3 days after NIV initiation.
The primary endpoint is the development of a facial pressure ulcer within the first 3 days after NIV initiation
Secondary Outcome Measures
Change of the delay for facial pressure ulcers to appear in the experimental arm, compared to the control arm
This secondary endpoint is the delay (in hours) between NIV initiation and the development of a facial pressure ulcer.
Change of the severity of facial pressure ulcers in the experimental arm, compared to the control arm
This secondary endpoint is the highest facial pressure ulcer severity score observed during patient hospitalization. This score is evaluated according to the National Pressure Ulcer Advisory Panel guidelines (Edsberg LE et al., 2016). Stage 1 pressure injury (the less severe score) corresponds to intact skin with a localized area of nonblanchable erythema. Stage 2 pressure injury corresponds to partial-thickness skin loss with exposed dermis. Stage 3 pressure injury corresponds to full-thickness skin loss. Stage 4 pressure injury (the most severe score) corresponds to full-thickness skin and tissue loss.
Change of the patient comfort in the experimental arm, compared to the control arm
This secondary endpoint is the comfort patient score at 24 hours after NIV initiation. This score is a numeric scale, validated for NIV (Lemyze M et al., 2013 ; Gregoretti C et al., 2002), going from 1 to 5 (1: very uncomfortable ; 2: uncomfortable ; 3: acceptable ; 4: quite comfortable ; 5: comfortable).
Change of the incidence of mask changes related to interface intolerance in the experimental arm, compared to the control arm
This secondary endpoint is the incidence of mask changes related to interface intolerance during patient hospitalization.
Change of the incidence of NIV failure in the experimental arm, compared to the control arm
This secondary endpoint is the incidence of NIV failure defined as the need to resort to intubation or palliative care (in the case of a do-not-intubate order) during patient hospitalization. NIV failures may be caused by refractory respiratory acidosis, refractory hypoxemia, pressure ulcers, interface intolerance, excessive unintentional air leaks or shock.
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT04102735
Brief Title
Under the Nose Face Mask to Prevent Facial Pressure Ulcers During NIV for Acute Hypercapnic Respiratory Failure (AHRF)
Acronym
UNDER PRESSURE
Official Title
UNDER the Nose vs. Over the Nose Face Mask to Prevent Facial PRESSURE Ulcers During Face Mask-noninvasive Ventilation for Acute Hypercapnic Respiratory Failure
Study Type
Interventional
2. Study Status
Record Verification Date
March 2022
Overall Recruitment Status
Completed
Study Start Date
November 21, 2018 (Actual)
Primary Completion Date
October 3, 2021 (Actual)
Study Completion Date
October 3, 2021 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Centre Hospitalier Arras
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
Noninvasive ventilation (NIV) is essential to treat acute hypercapnic respiratory failure. However, facial pressure ulcers appearing during facemask-delivered noninvasive ventilation are a source of NIV failure by interface intolerance.
A Philips facemask (model : AF541 SE Oro-Nasal mask) has the particularity to display two options for its positioning : a usually used "over-the-nose" positioning or an "under-the-nose" positioning that is supposed to reduce the incidence of facial pressure ulcers while keeping in the same time the qualities of a standard facemask.
The goal of this controlled randomized trial is to test the hypothesis that the "under-the-nose" positioning actually reduces the incidence of facial pressure ulcers, compared to the usually used "over-the-nose" positioning.
Results of this trial should lead to the proposition of a new interface strategy to prevent facial pressure ulcers and therefore to improve the tolerance of NIV via the use of facemasks displaying an "under-the-nose" positioning.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Acute Hypercapnic Respiratory Failure
Keywords
facial pressure ulcers, noninvasive ventilation, acute hypercapnic respiratory failure
7. Study Design
Primary Purpose
Other
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
108 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Over-the-nose facemask
Arm Type
Active Comparator
Arm Description
The AF541 oro-nasal mask is used with the over-the-nose mask cushion.
Arm Title
Under-the-nose facemask
Arm Type
Experimental
Arm Description
The AF541 oro-nasal mask is used with the under-the-nose mask cushion.
Intervention Type
Device
Intervention Name(s)
Under-the-nose facemask
Intervention Description
Patients with acute hypercapnic respiratory failure that need noninvasive ventilation and are randomized in the experimental group will receive the AF541 facemask used with the under-the-nose cushion.
Intervention Type
Device
Intervention Name(s)
Over-the-nose facemask
Intervention Description
Patients with acute hypercapnic respiratory failure that need non-invasive ventilation and are randomized in the comparator group will receive the AF541 facemask used with the over-the-nose cushion.
Primary Outcome Measure Information:
Title
Change of the incidence of facial pressure ulcers in the experimental arm compared to the control arm, within the first 3 days after NIV initiation.
Description
The primary endpoint is the development of a facial pressure ulcer within the first 3 days after NIV initiation
Time Frame
3 days after NIV initiation
Secondary Outcome Measure Information:
Title
Change of the delay for facial pressure ulcers to appear in the experimental arm, compared to the control arm
Description
This secondary endpoint is the delay (in hours) between NIV initiation and the development of a facial pressure ulcer.
Time Frame
7 days after NIV initiation
Title
Change of the severity of facial pressure ulcers in the experimental arm, compared to the control arm
Description
This secondary endpoint is the highest facial pressure ulcer severity score observed during patient hospitalization. This score is evaluated according to the National Pressure Ulcer Advisory Panel guidelines (Edsberg LE et al., 2016). Stage 1 pressure injury (the less severe score) corresponds to intact skin with a localized area of nonblanchable erythema. Stage 2 pressure injury corresponds to partial-thickness skin loss with exposed dermis. Stage 3 pressure injury corresponds to full-thickness skin loss. Stage 4 pressure injury (the most severe score) corresponds to full-thickness skin and tissue loss.
Time Frame
7 days after NIV initiation
Title
Change of the patient comfort in the experimental arm, compared to the control arm
Description
This secondary endpoint is the comfort patient score at 24 hours after NIV initiation. This score is a numeric scale, validated for NIV (Lemyze M et al., 2013 ; Gregoretti C et al., 2002), going from 1 to 5 (1: very uncomfortable ; 2: uncomfortable ; 3: acceptable ; 4: quite comfortable ; 5: comfortable).
Time Frame
24 hours after NIV initiation
Title
Change of the incidence of mask changes related to interface intolerance in the experimental arm, compared to the control arm
Description
This secondary endpoint is the incidence of mask changes related to interface intolerance during patient hospitalization.
Time Frame
7 days after NIV initiation
Title
Change of the incidence of NIV failure in the experimental arm, compared to the control arm
Description
This secondary endpoint is the incidence of NIV failure defined as the need to resort to intubation or palliative care (in the case of a do-not-intubate order) during patient hospitalization. NIV failures may be caused by refractory respiratory acidosis, refractory hypoxemia, pressure ulcers, interface intolerance, excessive unintentional air leaks or shock.
Time Frame
7 days after NIV initiation
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Acute hypercapnic respiratory failure
Initiation of NIV
Estimated cumulative time of NIV upper than 12 hours for the first 48 hours of hospitalization
Exclusion Criteria:
Contraindication for NIV (respiratory arrest, impossibility to fit the mask)
Intubated patient
Patient with a tracheostomy
Post-extubation respiratory failure
Patient exhibiting facial ulcers or skin lesions located at the insertion points of the mask before its hospitalization
Person declining NIV
Pregnancy
Dying person
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Malcolm LEMYZE, MD
Organizational Affiliation
Centre Hospitalier Arras
Official's Role
Principal Investigator
Facility Information:
Facility Name
Centre Hospitalier Arras
City
Arras
Country
France
Facility Name
Centre Hospitalier Lens
City
Lens
Country
France
12. IPD Sharing Statement
Citations:
PubMed Identifier
27749790
Citation
Edsberg LE, Black JM, Goldberg M, McNichol L, Moore L, Sieggreen M. Revised National Pressure Ulcer Advisory Panel Pressure Injury Staging System: Revised Pressure Injury Staging System. J Wound Ostomy Continence Nurs. 2016 Nov/Dec;43(6):585-597. doi: 10.1097/WON.0000000000000281.
Results Reference
background
PubMed Identifier
23263582
Citation
Lemyze M, Mallat J, Nigeon O, Barrailler S, Pepy F, Gasan G, Vangrunderbeeck N, Grosset P, Tronchon L, Thevenin D. Rescue therapy by switching to total face mask after failure of face mask-delivered noninvasive ventilation in do-not-intubate patients in acute respiratory failure. Crit Care Med. 2013 Feb;41(2):481-8. doi: 10.1097/CCM.0b013e31826ab4af.
Results Reference
background
PubMed Identifier
11904656
Citation
Gregoretti C, Confalonieri M, Navalesi P, Squadrone V, Frigerio P, Beltrame F, Carbone G, Conti G, Gamna F, Nava S, Calderini E, Skrobik Y, Antonelli M. Evaluation of patient skin breakdown and comfort with a new face mask for non-invasive ventilation: a multi-center study. Intensive Care Med. 2002 Mar;28(3):278-84. doi: 10.1007/s00134-002-1208-7. Epub 2002 Feb 6.
Results Reference
background
Learn more about this trial
Under the Nose Face Mask to Prevent Facial Pressure Ulcers During NIV for Acute Hypercapnic Respiratory Failure (AHRF)
We'll reach out to this number within 24 hrs